Key points
- Commercial sales increased 16.7% to $138.4m
- Total revenue increased 16.1% to $150.0m
- Positive EBITDA of $12.1m and NPAT of $7.3m
Full summary
Polynovo Ltd announced its financial results for the year ended 30 June 2026. The company reported total revenue of $150.0 million, a 16.1% increase from the previous year, driven by a 16.7% rise in commercial sales to $138.4 million. Gross margin was 89.0%, down from 95.6% in the prior period, primarily due to changes in inventories of finished goods. EBITDA increased by 8.1% to $12.1 million, while net profit after tax was $7.3 million, reflecting non-recurring impacts such as the R&D Innovation Centre fire. The company also highlighted significant progress in manufacturing, clinical trials, and market expansion.
Guidance
FY26 total revenue $150.0m, commercial sales $138.4m, EBITDA $12.1m, NPAT $7.3m
Outlook
Polynovo plans to leverage its growing core franchise, expand NovoSorb® MTX adoption, and pursue strategic opportunities to extend the NovoSorb® platform in FY27.